In a report issued on September 13, Cory Kasimov from J.P. Morgan maintained a Hold rating on Gilead Sciences (GILD). The company’s shares closed last Tuesday at $66.44.
According to TipRanks.com, Kasimov is a 5-star analyst with an average return of 19.4% and a 54.6% success rate. Kasimov covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Alexion Pharmaceuticals, and BioMarin Pharmaceutical.
Currently, the analyst consensus on Gilead Sciences is a Moderate Buy with an average price target of $80.12, implying a 19.5% upside from current levels. In a report released yesterday, Raymond James also maintained a Hold rating on the stock.
See today’s analyst top recommended stocks >>
The company has a one-year high of $85.97 and a one-year low of $60.89. Currently, Gilead Sciences has an average volume of 8.31M.
Based on the recent corporate insider activity of 66 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of GILD in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firms primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster, CA.
Read More on GILD: